Textbook of clinical trials: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 10: Line 10:


HIPAA reidentification of patients and patient privacy
HIPAA reidentification of patients and patient privacy


'''Regulatory issues and pathways in clinical trials'''
'''Regulatory issues and pathways in clinical trials'''
Line 25: Line 21:
[[510K Pathway|510K pathway]]
[[510K Pathway|510K pathway]]


 
{{ColBreak}}
 
 
 
'''Designing Clinical Trials'''
'''Designing Clinical Trials'''


Line 38: Line 31:


[[Phase II clinical trial|Phase 2 trials]]
[[Phase II clinical trial|Phase 2 trials]]
{{ColBreak}}


Advancing from phase 2 to a phase 3 trial
Advancing from phase 2 to a phase 3 trial
Line 51: Line 43:


[[Stratification]]
[[Stratification]]
 
{{ColBreak}}
[[Primary end point|Primary endpoint]]
[[Primary end point|Primary endpoint]]


Line 63: Line 55:


[[Abbreviations used in clinical trials]]
[[Abbreviations used in clinical trials]]


'''Operationalizing Clinical Trials'''
'''Operationalizing Clinical Trials'''


Principal investigator role
Principal investigator role
{{ColBreak}}
 
Executive committee role
Executive committee role


Line 75: Line 65:


Nurse coordinator clinical research associate role
Nurse coordinator clinical research associate role
 
{{ColBreak}}
Monitor role
Monitor role


Line 97: Line 87:


[[Randomization]]
[[Randomization]]
{{ColBreak}}
 
[[Blinding]]
[[Blinding]]


Line 103: Line 93:


[[Electronic data capture|Electronic data collection]]
[[Electronic data capture|Electronic data collection]]
 
{{ColBreak}}
Schedule of events
Schedule of events


Line 118: Line 108:
Protocol adherence
Protocol adherence


Storage and handling of investigational product
Storage and handling of the  investigational product
 
{{ColBreak}}
Data management and designing an electronic data capture form
Data management and designing an electronic data capture form


Line 125: Line 115:


Study completion and close out
Study completion and close out
{{ColBreak}}
 
Protocol amendments
Protocol amendments


Publication committee
Publication committee


'''Statistical Analysis of Clinical Trials'''
'''Statistical Analysis of Clinical Trials'''
Line 143: Line 129:


[[Student's t-test|Student's t tests]] and [[analysis of variance]]
[[Student's t-test|Student's t tests]] and [[analysis of variance]]
 
{{ColBreak}}
[[Chi-square test|Chi square analysis]] and [[Fisher's exact test]]
[[Chi-square test|Chi square analysis]] and [[Fisher's exact test]]


Line 157: Line 143:


Net clinical benefit analyses
Net clinical benefit analyses
{{ColBreak}}
 
Cost effectiveness analyses
Cost effectiveness analyses


Line 164: Line 150:
Interim analyses and [[Futility in clinical research|futility analyses]]
Interim analyses and [[Futility in clinical research|futility analyses]]


Reporting results and how to write a manuscript
Reporting results  
{{ColBreak}}
How to write a manuscript


[[Meta-analysis]]
[[Meta-analysis]]

Revision as of 14:01, 25 October 2019


Ethical Issues

Helsinki agreement

Informed consent

Investigational Review Board (IRB)

HIPAA reidentification of patients and patient privacy

Regulatory issues and pathways in clinical trials

The 1572 form and investigator responsibilities

Investigational new drug (IND) application

Investigational new drug or device exemption

510K pathway

Designing Clinical Trials

Randomized controlled trials versus observational studies

Phase 1 trials

Pharmacokinetic (PK) and pharmcodynamic (PD) assessment

Phase 2 trials

Advancing from phase 2 to a phase 3 trial

Phase 3 trials

Parallel versus dose escalation studies

Hypothesis generation

Inclusion and exclusion criteria

Stratification

Primary endpoint

Secondary endpoints and exploratory endpoints

Surrogate endpoints

Sample size and power calculations

Protocol creation

Abbreviations used in clinical trials

Operationalizing Clinical Trials

Principal investigator role

Executive committee role

Steering committee role

Nurse coordinator clinical research associate role

Monitor role

Sponsor role

Randomization service

Central laboratory facility

EKG core laboratory

Angiographic core laboratory

MRI core laboratory

Genetics core laboratory

Biomarker core laboratory

Identification of sites

Randomization

Blinding

Recruitment of study participants

Electronic data collection

Schedule of events

Concomitant medications

Clinical event committee or event adjudication committee

Adverse events, serious adverse events and serious unexpected events

Data safety monitoring board (DSMB)

Study drug discontinuation, withdrawal of consent, incomplete follow up and lost to follow up patients

Protocol adherence

Storage and handling of the investigational product

Data management and designing an electronic data capture form

Source documents

Study completion and close out

Protocol amendments

Publication committee

Statistical Analysis of Clinical Trials

Cleaning a dataset

Summary statistics

Intent to treat versus modified intent to treat versus as treated

Student's t tests and analysis of variance

Chi square analysis and Fisher's exact test

Logistic regression

Multivariate modeling

Survival analysis

Handling missing data

Subgroup and interaction analyses

Net clinical benefit analyses

Cost effectiveness analyses

Quality adjusted life year analyses

Interim analyses and futility analyses

Reporting results

How to write a manuscript

Meta-analysis

Positive publication bias


Study Tools

GFR calculation

TIMI Risk Score

Grace Risk Score